menu search

Anaptys announces participation in november investor conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...

November 1, 2023, 9:15 am

Anaptys to present phase 1 data on anb032, its btla agonist antibody, at the 32nd eadv congress

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...

October 11, 2023, 9:15 am

anaptysbio's skin disease drug meets main goal in late-stage study

anaptysbio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main g...

October 9, 2023, 8:32 am

anaptysbio to present at the stifel 2023 immunology and inflammation virtual summit

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotech...

September 12, 2023, 9:15 am

anaptysbio- and gsk-partnered immuno-oncology agent jemperli (dostarlimab-gxly) plus chemotherapy approved in the u.s. for dmmr/msi-h primary advanced or recurrent endometrial cancer

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Fo...

July 31, 2023, 5:34 pm

anaptysbio: despite early successes, current situation does not impress

anaptysbio, Inc. had major deals with big pharma in past years. However, its current programs are not t...

July 7, 2023, 10:33 am

anaptysbio announces participation in upcoming investor conferences

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...

May 30, 2023, 8:15 pm

anaptysbio, inc. (anab) reports q1 loss, misses revenue estimates

anaptysbio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Es...

May 11, 2023, 7:02 pm

anaptysbio: upside could be lying ahead very nicely

US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and tak...

March 30, 2023, 11:44 pm

anaptysbio to participate in upcoming november investor conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- anaptysbio, Inc. (Nasdaq: ANAB), a clinical-stage biotechn...

November 9, 2022, 2:10 pm

anaptysbio, inc. (anab) reports q3 loss, misses revenue estimates

anaptysbio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, ...

November 8, 2022, 7:33 pm

anaptysbio, inc. (anab) soars 6.2%: is further upside left in the stock?

anaptysbio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest ...

April 26, 2022, 8:17 am

anaptysbio to discontinue imsidolimab development in moderate-to-severe acne

anaptysbio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did no...

March 15, 2022, 8:22 am


Search within

Pages Search Results: